{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:43:06Z","timestamp":1794040986063,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013103","name":"QIMR Berghofer Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      New anti-malarial therapeutics are required to counter the threat of increasing drug resistance. Malaria volunteer infection studies (VIS), particularly the induced blood stage malaria (IBSM) model, play a key role in accelerating anti-malarial drug development. Supply of the reference 3D7-V2\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria cell bank (MCB) is limited. This study aimed to develop a new MCB, and compare the safety and infectivity of this MCB with the existing 3D7-V2 MCB, in a VIS. A second bank (3D7-V1) developed in 1995 was also evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The 3D7-V2 MCB was expanded in vitro using a bioreactor to produce a new MCB designated 3D7-MBE-008. This bank and 3D7-V1 were then evaluated using the IBSM model, where healthy participants were intravenously inoculated with blood-stage parasites. Participants were treated with artemether-lumefantrine when parasitaemia or clinical thresholds were reached. Safety, infectivity and parasite growth and clearance were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The in vitro expansion of 3D7-V2 produced 200 vials of the 3D7-MBE-008 MCB, with a parasitaemia of 4.3%. This compares to 0.1% in the existing 3D7-V2 MCB, and\u2009&lt;\u20090.01% in the 3D7-V1 MCB. All four participants (two per MCB) developed detectable\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      infection after inoculation with approximately 2800 parasites. For the 3D7-MBE-008 MCB, the parasite multiplication rate of 48\u00a0h (PMR\n                      <jats:sub>48<\/jats:sub>\n                      ) using non-linear mixed effects modelling was 34.6 (95% CI 18.5\u201364.6), similar to the parental 3D7-V2 line; parasitaemia in both participants exceeded 10,000\/mL by day 8. Growth of the 3D7-V1 was slower (PMR\n                      <jats:sub>48<\/jats:sub>\n                      of 11.5 [95% CI 8.5\u201315.6]), with parasitaemia exceeding 10,000 parasites\/mL on days 10 and 8.5. Rapid parasite clearance followed artemether-lumefantrine treatment in all four participants, with clearance half-lives of 4.01 and 4.06 (weighted mean 4.04 [95% CI 3.61\u20134.57]) hours for 3D7-MBE-008 and 4.11 and 4.52 (weighted mean 4.31 [95% CI 4.16\u20134.47]) hours for 3D7-V1. A total of 59 adverse events occurred; most were of mild severity with three being severe in the 3D7-MBE-008 study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The safety, growth and clearance profiles of the expanded 3D7-MBE-008 MCB closely resemble that of its parent, indicating its suitability for future studies.\n                      <jats:italic>Trial Registration:<\/jats:italic>\n                      Australian New Zealand Clinical Trials registry numbers: P3487 (3D7-V1): ACTRN12619001085167. P3491 (3D7-MBE-008): ACTRN12619001079134\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-03627-z","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T12:17:14Z","timestamp":1613564234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Development and evaluation of a new Plasmodium falciparum 3D7 blood stage malaria cell bank for use in malaria volunteer infection studies"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"actrn12619001085167","registry":"10.18810\/anzctr"},{"clinical-trial-number":"actrn12619001079134","registry":"10.18810\/anzctr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-8975","authenticated-orcid":false,"given":"Stephen D.","family":"Woolley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rebelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Llewellyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Marquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona H.","family":"Amante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Trenholme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg J.","family":"Moehrle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"3627_CR1","doi-asserted-by":"publisher","first-page":"a025619","DOI":"10.1101\/cshperspect.a025619","volume":"7","author":"D Menard","year":"2017","unstructured":"Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7:a025619.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3627_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/parasite\/2014059","volume":"21","author":"S Sinha","year":"2014","unstructured":"Sinha S, Medhi B, Sehgal R. Challenges of drug-resistant malaria. Parasite. 2014;21:61.","journal-title":"Parasite"},{"key":"3627_CR3","unstructured":"WHO. Artemisinin and artemisinin-based combination therapy resistance. Status report. Geneva, World Health Organization, Global Malaria Programme, 2016."},{"key":"3627_CR4","doi-asserted-by":"publisher","first-page":"e1002456","DOI":"10.1371\/journal.pmed.1002456","volume":"14","author":"RN Rabinovich","year":"2017","unstructured":"Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, et al. malERA: an updated research agenda for malaria elimination and eradication. PLoS Med. 2017;14:e1002456.","journal-title":"PLoS Med."},{"key":"3627_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.pt.2012.09.001","volume":"28","author":"CR Engwerda","year":"2012","unstructured":"Engwerda CR, Minigo G, Amante FH, McCarthy JS. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 2012;28:515\u201321.","journal-title":"Trends Parasitol"},{"key":"3627_CR6","doi-asserted-by":"crossref","first-page":"e00479","DOI":"10.1128\/IAI.00479-17","volume":"86","author":"DI Stanisic","year":"2018","unstructured":"Stanisic DI, Mccarthy JS, Good MF. Controlled human malaria infection: applications, advances, and challenges. Infect Immun. 2018;86:e00479-e517.","journal-title":"Infect Immun"},{"key":"3627_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2018.05.006","volume":"42","author":"HR van Huijsduijnen","year":"2018","unstructured":"van Huijsduijnen HR, Wells TN. The antimalarial pipeline. Curr Opin Pharmacol. 2018;42:1\u20136.","journal-title":"Curr Opin Pharmacol."},{"key":"3627_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nrd4573","volume":"14","author":"TN Wells","year":"2015","unstructured":"Wells TN, van Huijsduijnen HR, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14:424\u201342.","journal-title":"Nat Rev Drug Discov."},{"key":"3627_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12936-016-1511-3","volume":"15","author":"JS McCarthy","year":"2016","unstructured":"McCarthy JS, Ruckle T, Djeriou E, Cantalloube C, Ter-Minassian D, Baker M, et al. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malar J. 2016;15:469.","journal-title":"Malar J."},{"key":"3627_CR10","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1093\/jac\/dkw174","volume":"71","author":"JS McCarthy","year":"2016","unstructured":"McCarthy JS, Baker M, O\u2019Rourke P, Marquart L, Griffin P, van Huijsduijnen HR, et al. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. J Antimicrob Chemother. 2016;71:2620\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"3627_CR11","first-page":"948","volume":"221","author":"J Woodford","year":"2020","unstructured":"Woodford J, Collins KA, Odedra A, Wang C, Kyung Jang I, Domingo GJ, et al. An experimental human blood-stage model for studying Plasmodium malariae infection. J Infect Dis. 2020;221:948\u201355.","journal-title":"J Infect Dis"},{"key":"3627_CR12","doi-asserted-by":"crossref","unstructured":"Alkema M, Reuling IJ, de Jong GM, Lanke K, Coffeng LE, van Gemert G-J, et al. A randomized clinical trial to compare Plasmodium falciparum gametocytemia and infectivity after blood-stage or mosquito bite\u2013induced controlled malaria infection. J Infect Dis; 2020; jiaa157.","DOI":"10.1093\/infdis\/jiaa157"},{"key":"3627_CR13","unstructured":"NCT02927145. A challenge study to assess the safety, immunogenicity and efficacy of a malaria vaccine candidate. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/. Accessed 28 September 2020."},{"key":"3627_CR14","unstructured":"ANZCTR Trial ID: NCT03542149. Phase 1b to assess safety, tolerability, pharmacokinetic profile, and antimalarial activity of single doses of co-administered OZ439and PQP against early Plasmodium falciparum blood stage infection in healthy adult volunteers. 2018. http:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=7116&isClinicalTrial=True. Accessed 28 September 2020."},{"key":"3627_CR15","unstructured":"ANZCTR Trial ID: ACTRN12619001215112. Open label study using the P. falciparum induced blood stage malaria (IBSM) model to determine the safety and tolerablity and to characterise the antimalarial activity of a single-dose oral administration of ZY-19489. 2019. https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12619001215112. Accessed 28 September 2020."},{"key":"3627_CR16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S1473-3099(19)30611-5","volume":"20","author":"AH Gaur","year":"2020","unstructured":"Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, et al. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a\/b trial. Lancet Infect Dis. 2020;20:964\u201375.","journal-title":"Lancet Infect Dis"},{"key":"3627_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12936-018-2435-x","volume":"17","author":"R Pawliw","year":"2018","unstructured":"Pawliw R, Farrow R, Sekuloski S, Jennings H, Healer J, Phuong T, et al. A bioreactor system for the manufacture of a genetically modified Plasmodium falciparum blood stage malaria cell bank for use in a clinical trial. Malar J. 2018;17:283.","journal-title":"Malar J."},{"key":"3627_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0140-6736(02)09784-2","volume":"360","author":"DJ Pombo","year":"2002","unstructured":"Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360:610\u20137.","journal-title":"Lancet"},{"key":"3627_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4269\/ajtmh.1997.57.495","volume":"57","author":"Q Cheng","year":"1997","unstructured":"Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-cartwright L, Creasey A, et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg. 1997;57:495\u2013500.","journal-title":"Am J Trop Med Hyg"},{"key":"3627_CR20","doi-asserted-by":"publisher","first-page":"e1003203","DOI":"10.1371\/journal.pmed.1003203","volume":"17","author":"RE Watts","year":"2020","unstructured":"Watts RE, Odedra A, Marquart L, Webb L, Abd-Rahman AN, Cascales L, et al. Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: a pilot and a randomised volunteer infection study in Australia. PLoS Med. 2020;17:e1003203.","journal-title":"PLoS Med"},{"key":"3627_CR21","unstructured":"ANZCTR Trial ID: ACTRN12617000824369. Safety and immunogeneticity study of a genetically attenuated malaria vaccine candidate in healty volunteers. 2017. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=372949. Accessed 28 September 2020."},{"key":"3627_CR22","unstructured":"PIC\/S guide to Good Manufacturing Practice for medicinal products Annex 13\u2014Manufacture of investigational medicinal products. The Australian code of Good Manufacturing Practice (GMP) for blood and blood components, human tissues and human cellular therapy products. https:\/\/www.tga.gov.au\/publication\/pe009-13-pics-guide-gmp-medicinal-products. Accessed 28 September 2020."},{"key":"3627_CR23","volume-title":"British Pharmacopoeia 2016","author":"British Pharmacopoeia Commission","year":"2016","unstructured":"British Pharmacopoeia Commission. British Pharmacopoeia 2016. London: TSO; 2016."},{"key":"3627_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1475-2875-10-48","volume":"10","author":"RJ Rockett","year":"2011","unstructured":"Rockett RJ, Tozer SJ, Peatey C, Bialasiewicz S, Whiley DM, Nissen MD, et al. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar J. 2011;10:48.","journal-title":"Malar J"},{"key":"3627_CR25","first-page":"963","volume":"221","author":"LF Wockner","year":"2020","unstructured":"Wockner LF, Hoffmann I, Webb L, Mordm\u00fcller B, Murphy SC, Kublin JG, et al. Growth rate of Plasmodium falciparum: analysis of parasite growth data from malaria volunteer infection studies. J Infect Dis. 2020;221:963\u201372.","journal-title":"J Infect Dis"},{"key":"3627_CR26","first-page":"279","volume-title":"Handbook of research synthesis and meta-analysis","author":"Analysing effect sizes","year":"2009","unstructured":"Analysing effect sizes. Fixed-effects models. In: Cooper H, Hedges LV, Valentine JC, editors. Handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009. p. 279\u201394.","edition":"2"},{"key":"3627_CR27","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1128\/AAC.04942-14","volume":"59","author":"L Marquart","year":"2015","unstructured":"Marquart L, Baker M, O\u2019Rourke P, McCarthy JS. Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. Antimicrob Agents Chemother. 2015;59:4249\u201359.","journal-title":"Antimicrob Agents Chemother"},{"key":"3627_CR28","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1128\/AAC.00340-15","volume":"59","author":"DS Stein","year":"2015","unstructured":"Stein DS, Jain JP, Kangas M, Lefevre G, Machineni S, Griffin P, et al. Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine. Antimicrob Agents Chemother. 2015;59:3493\u2013500.","journal-title":"Antimicrob Agents Chemother"},{"key":"3627_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4269\/ajtmh.17-0754","volume":"98","author":"J Woodford","year":"2018","unstructured":"Woodford J, Shanks GD, Griffin P, Chalon S, McCarthy JS. The dynamics of liver function test abnormalities after malaria infection: a retrospective observational study. Am J Trop Med Hyg. 2018;98:1113\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3627_CR30","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.4269\/ajtmh.20-0491","volume":"103","author":"A Odedra","year":"2020","unstructured":"Odedra A, Webb L, Marquart L, Britton LJ, Chalon S, Moehrle JJ, et al. Liver Function Test abnormalities in experimental and clinical Plasmodium vivax Infection. Am J Trop Med Hyg. 2020;103:1910\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"3627_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4269\/ajtmh.19-0846","volume":"103","author":"MF Chughlay","year":"2020","unstructured":"Chughlay MF, Akakpo S, Odedra A, Csermak-Renner K, Djeriou E, Winnips C, et al. Liver Enzyme elevations in Plasmodium falciparum volunteer infection studies: findings and recommendations. Am J Trop Med Hyg. 2020;103:378\u201393.","journal-title":"Am J Trop Med Hyg"},{"key":"3627_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ebiom.2018.09.018","volume":"36","author":"IJ Reuling","year":"2018","unstructured":"Reuling IJ, de Jong GM, Yap XZ, Asghar M, Walk J, van de Schans LA, et al. Liver Injury in uncomplicated malaria is an overlooked phenomenon: an observational study. EBioMedicine. 2018;36:131\u20139.","journal-title":"EBioMedicine"},{"key":"3627_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ebiom.2018.10.023","volume":"37","author":"BR Moore","year":"2018","unstructured":"Moore BR. Liver injury in uncomplicated malaria: an overlooked phenomenon. EBioMedicine. 2018;37:15\u20136.","journal-title":"EBioMedicine"},{"key":"3627_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12936-017-2108-1","volume":"16","author":"ME van Wolfswinkel","year":"2017","unstructured":"van Wolfswinkel ME, Langenberg MCC, Wammes LJ, Sauerwein RW, Koelewijn R, Hermsen CC, et al. Changes in total and differential leukocyte counts during the clinically silent liver phase in a controlled human malaria infection in malaria-na\u00efve Dutch volunteers. Malar J. 2017;16:457.","journal-title":"Malar J"},{"key":"3627_CR35","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.1128\/IAI.68.10.6087-6089.2000","volume":"68","author":"L Hviid","year":"2000","unstructured":"Hviid L, Kemp K. What is the cause of lymphopenia in malaria? Infect Immun. 2000;68:6087\u20139.","journal-title":"Infect Immun"},{"key":"3627_CR36","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1016\/j.vaccine.2016.10.027","volume":"34","author":"EB Brickley","year":"2016","unstructured":"Brickley EB, Coulibaly M, Gabriel EE, Healy SA, Hume JC, Sagara I, et al. Utilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: a systematic review of methods and case study. Vaccine. 2016;34:5863\u201370.","journal-title":"Vaccine"},{"key":"3627_CR37","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jit394","volume":"208","author":"JS McCarthy","year":"2013","unstructured":"McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, Looke D, et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis. 2013;208:1688\u201394.","journal-title":"J Infect Dis"},{"key":"3627_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pt.2016.11.001","volume":"33","author":"RO Payne","year":"2017","unstructured":"Payne RO, Griffin PM, McCarthy JS, Draper SJ. Plasmodium vivax controlled human malaria infection\u2014Progress and prospects. Trends Parasitol. 2017;33:141\u201350.","journal-title":"Trends Parasitol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03627-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03627-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03627-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:27:29Z","timestamp":1628598449000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03627-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3627"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03627-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-90708\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-90708\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-90708\/v2","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"9 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was given by QIMR Berghofer Human Research Ethics Committee (HREC), with further ethical approval given by Lifeblood (formerly Australian Red Cross Blood Service) HREC for <i>P. falciparum<\/i> 3D7 MBE-008. All participants gave written informed consent before enrolment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}